Navigation Links
Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets
Date:10/7/2010

is currently being evaluated in the BR.26 clinical trial, a Phase 3, double-blind, placebo-controlled, randomized study in patients with stage IIIB/IV NSCLC who have progressive disease following standard chemotherapy and EGFR inhibitor therapy.(3) BR.26 is led by the NCIC Clinical Trials Group (CTG).(3)

  • Crizotinib (PF-02341066)

Updated data on crizotinib (PF-02341066), a first-in-class, oral ALK inhibitor, will also be presented, from the ongoing expansion cohort from the Phase 1 study evaluating the compound in patients with ALK-positive advanced NSCLC (Abstract #366PD, October 10).(4)

  • Sunitinib

Pfizer will also present results from SUN 1087, a Phase 3 trial evaluating sunitinib plus erlotinib compared to erlotinib alone in patients with advanced NSCLC who have received at least one previous treatment with a platinum-based regimen (Abstract #LBA6, October 11).(5)  In August, Pfizer announced that this study demonstrated a statistically significant improvement in progression-free survival but not in overall survival.  Overall survival was the primary endpoint of the study and progression free survival was the secondary endpoint of the study.

Pfizer will also present progression-free survival (PFS) data as determined by blinded independent central review (BICR) from the pivotal, placebo-controlled SUN 1111 Phase 3 trial evaluating sunitinib in patients with progressive, well-differentiated pancreatic neuroendocrine tumor (NET) (Abstract #747P, October 9).(6)

  • Figitumumab

Results from a Phase 1/2 study evaluating figitumumab (CP-751,871), a selective fully human IgG2 monoclonal antibody against the IGF-1R (insulin-like growth factor 1 receptor) pathway, in patients with refractory Ewing's sarcoma and other sarcomas will be presented in a Proffe
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
4. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. MannKind Addresses Pfizers Announcement Regarding Exubera
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
11. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Pa. , Aug. 27, 2015  PinnacleHealth CardioVascular Institute ... and second in the United States ... new type of stent for blockages in the main artery ... within the artery and potentially less risk for stent fracture ... is a prospective, single-arm, multicenter clinical trial of the BioMimics ...
(Date:8/27/2015)... Aug. 27, 2015  Lightwave Logic, Inc. (OTCQB: ... of Next Generation Photonic Devices and Non-Linear ... high speed fiber-optic data communications and optical computing, ... has been appointed to the Company,s Board of ... field of optoelectronics is widely recognized with wide-ranging ...
(Date:8/27/2015)... , Aug. 27, 2015  CytomX Therapeutics, ... the treatment of cancer, today announced that ... the company,s Board of Directors, has been appointed ... at Eli Lilly and AstraZeneca, and also oversaw ... approved checkpoint inhibitor, at Bristol-Myers Squibb and the ...
Breaking Medicine Technology:First Pennsylvania Patient Treated in Landmark Vascular Study 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 3Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3
... 3, 2011 Valeant Pharmaceuticals International, Inc. (NYSE: ... that Valeant Pharmaceuticals International ("Valeant"), its wholly owned indirect ... principal amount of senior unsecured notes (the "Notes"). ... Securities Act of 1933, as amended (the "Securities Act"), ...
... Feb. 3, 2011 Unilife Corporation ("Unilife" or the "Company") ... it has appointed Dr. Ramin Mojdeh, formerly Vice President and ... and Worldwide Vice President of Research and Development, BD Medical, ... effective February 7, 2011. Dr. Mojdeh comes ...
Cached Medicine Technology:Valeant Launches Senior Notes Offering 2Valeant Launches Senior Notes Offering 3Unilife Appoints Dr. Ramin Mojdeh as Chief Operating Officer 2Unilife Appoints Dr. Ramin Mojdeh as Chief Operating Officer 3Unilife Appoints Dr. Ramin Mojdeh as Chief Operating Officer 4Unilife Appoints Dr. Ramin Mojdeh as Chief Operating Officer 5
(Date:8/27/2015)... Florida (PRWEB) , ... August 28, 2015 , ... This ... to ensure that patients are always scheduled for the next visit, their authorizations are ... here . , According to Jason Barnes, COO for Genesis Chiropractic Software, growing ...
(Date:8/27/2015)... ... August 27, 2015 , ... In the addiction treatment industry, some ... months later, relapsing and returning again, all at great cost to them and their ... living homes or soon after leaving facilities who claim to have given addicts tools ...
(Date:8/27/2015)... ... August 27, 2015 , ... According to an article published August ... new guidelines to educate doctors and patients on the best practices for type 2 ... in 2007, so the new version is taking into account nearly a decade of ...
(Date:8/27/2015)... , ... August 27, 2015 , ... ... enter the exploding legal marijuana industry with the launch of its Doobster platform, ... legal marijuana to order products from their smart phones and tablets. Well, ...
(Date:8/27/2015)... VA (PRWEB) , ... August 27, 2015 , ... The ... will now be offering Kybella, a cutting-edge, noninvasive procedure to improve submental fat. ... chin, Kybella provides permanent results without surgery. Dr. Kulak is the only Board ...
Breaking Medicine News(10 mins):Health News:A New Webinar Teaches Chiropractors How to Use Compliance Alerts to Manage Patient Relationships 2Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 2Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 3Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 2Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 3Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 2Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 3Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 4Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 5Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3
... Network is very near to achieving one of today’s Science ... health conditions.// ,As well as from the UGR, ... and Reus also took part in this study, concluding that ... small amounts by human beings and present in many types ...
... medical disorder in pregnancy, adversely affecting maternal and ... control and treatment of anemia during pregnancy, the ... majority of women present late. ... consequences that extend over generations. Girls born underweight ...
... Dev has launched a seven-day camp in this Taj Mahal ... other licentious activities.// ,Ram Dev, who enjoys wide following ... education being given to the young. ,'A balanced ... he said. ,Later speaking to journalists, Ram Dev ...
... and healthcare inequalities may have the most significant ... (CRC) between African// Americans and Caucasians, according to ... 2007 issue of CANCER, a peer-reviewed journal of ... from published studies demonstrated that when socioeconomic factors ...
... a handful of concerned citizens. Delhi, burning under the scorching ... voice on various issues that are pricking our fragile ecosystem. ... said Ravi Aggarwal of Toxics Link, an environmental NGO. 'The ... name of development needs to be addressed immediately and a ...
... electronic biometric attendance system to check late-coming teachers.// ... schools, but later will be extended to all schools in ... of Jaipur and five schools of Dausa. ,'Some ... be used on an experimental basis,' said Vasudev Devnani, Rajasthan's ...
Cached Medicine News:Health News:High Melatonin can Help Delay Ageing 2Health News:Social Factors Not Genetics Drive Racial Disparities in Colorectal Cancer Survival 2Health News:Earth Day Celebrated With Hopes of a Greener Tomorrow 2
...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
... Consensus knee system continues the "Consensus Concept" ... with the diversified experience of a Scientific ... knee system that incorporates state-of-the-art features. Consensus ... joint and implant stability and allow near ...
Profix total knee system is intended for cemented use only....
Medicine Products: